The Most Sensitive Bladder Cancer Test Available

Fluorescence In Situ Hybridization (FISH) is a urine-based, non-invasive genetic assay for both the diagnosis and surveillance of bladder cancer.

FISH provides the most sensitive detection of bladder cancer and hematuria for patients suspected of having bladder cancer.

Unsurpassed Sensitivity

  • Carcinoma in situ (CIS) detection rate is 100%
  • 97% overall sensitivity when used in conjunction with cystoscopy§
  • Higher sensitivity than cytology alone (81% vs. 58%)
  • Not affected by BCG therapy
  • Detects bladder cancer up to six months sooner
  • Detects upper tract urothelial carcinomas
  • Identifies abnormalities of chromosomes 3, 7, 17 and 9p21
  • 96% specificity

Exclusively at Bostwick Laboratories

  • Expert uropathology
  • Most FISH of any laboratory
  • Easy-to-use collection kit (one kit)
  • Three to five day turnaround time

Overview: Stage, Grade, Sensitivity, and Specificity of Test(s)

  pTa pTis pT1-pT4 OVR Se OVR Sp
FISH 65% 100% 95% 81% 96%
Cytology 47% 78% 60% 58% 98%
BTA 63% 94% 94% 78%  
NMP22       60-70% 60-70%
Dipstick 55% 100% 89% 74% 51%
Cystoscopy       74%  
Cysto-Cytology       89%  
Cysto-FISH       97%  

† Halling, et al. A Comparison of BTA Stat, Hemoglobin Dipstick, Talomerase, and Vysis UroVysion® Assays for the detection of Urothelial Carcinoma in Urine. Journal of Urology, May 2002. 167:2001-2006.

§ Karnes RT, Stewart CS, Jenkins RB, et al. A comparison of the combined sensitivity of cytoscopy and FISH versus the combined sensitivity of cystoscopy and urine cytology for the detection of urothelial carcinoma. Poster presented at: Annual Meeting of the American Urological Association; June 2-7, 2001; Anaheim, Calif. Poster 665.

‡ Specificity among patients without cystoscopic evidence or history of urothelial carcinoma. In its pivotal study, UroVysion® demonstrated 95.4% overall specificity among healthy volunteers or patients with no history of transitional cell carcinoma.

∆ Insufficiency rate based on Bostwick Laboratories® 2008 results.